[{"id":"042ee8b3-8da5-49b6-9335-5ef12826cf77","acronym":"TEDOPAM","url":"https://clinicaltrials.gov/study/NCT03806309","created_at":"2021-01-18T18:48:45.503Z","updated_at":"2024-07-02T16:35:54.651Z","phase":"Phase 2","brief_title":"Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT03806309 - TEDOPAM","lead_sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Tedopi (OSE 2101)"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 07/31/2019","start_date":" 07/31/2019","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-02-27"}]